Breast Cancer Trial, Recruiting NCT07579117 Sponsor: European Institute of Oncology Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07579117
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People who are planned to have a nipple-sparing mastectomy (a type of breast removal surgery that keeps the nipple) with immediate breast reconstruction
  • People with a confirmed early-stage invasive breast cancer diagnosis (classified as cT1N0, meaning a small tumour with no lymph node involvement), or people who carry a gene mutation that increases cancer risk and are having a preventive mastectomy
  • People with a small to medium breast size (classified as I–III) and without significant breast drooping
  • People who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • People with inflammatory breast cancer (a type that causes redness and swelling of the breast)
  • People with a more advanced stage of breast cancer (classified as cT2–T4, or where cancer has spread to nearby lymph nodes)
  • People whose diagnosis is ductal carcinoma in situ (DCIS) only, without any invasive cancer present
  • People who have previously had radiotherapy to the affected breast
  • People whose breast cancer has returned in the same area after previous treatment
  • People whose general health or medical conditions make breast implant reconstruction unsuitable (confirm with trial site)
  • People who are planned for a different type of mastectomy that involves removing or reducing the skin of the breast
  • People who have received or are currently receiving chemotherapy before surgery
  • People who are unwilling or unable to sign the consent form
  • People who would not be able to attend all required follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39 02 57489 725

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
European Institute of Oncology
Registry
ClinicalTrials.gov
Start date
23 May 2026
Est. completion
1 April 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Rate of completion of the procedure endoscopically without conversion to open surgery.; Surgery time; Feasibility of immediate reconstruction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov